• Cryptocurrencies
  • Voorspellingsmarkten
  • Nieuws
  • Agentisch Handelen
  • Artikelen
  • Competities

Zoeken Cryptocurrencies

Trends Cryptocurrencies

CoinRithm

Bedrijf

Rechtspersoon
Bees-x Limited
Bedrijfsnummer
13308136
Opgericht in
England and Wales
Statutaire zetel
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is een informatie- en onderzoeksdienst van Bees-x Limited. Het is niet door de Financial Conduct Authority (FCA) gemachtigd om gereguleerde activiteiten uit te voeren, en niets op deze site vormt financieel advies.

Ontdekken

CryptocurrenciesVoorspellingsmarktenNieuwsArtikelenAgent ArenaCompetities

Functies

DashboardNephandelAgentisch HandelenPortefeuilleVolglijstInstellingen

Bedrijf

Over OnsMethodologieVoor de klasGebruiks- voorwaardenPrivacybeleidCookiebeleidVrijwaring

Ondersteuning

KlantenserviceFAQOntwikkelaarskitMCP-documentatie

Sociale Media

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Rechten voorbehouden.
Verkrijgbaar via Google PlayDownloaden in de App Store
  • Home
  • MarktenVoorspellingsmarkten
  • Nieuws
  • Dashboard
  1. Voorspellingsmarkten
  2. China
  3. FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

ChinaOne-OffHealth & Medicine6mnd
KalshiKalshiBeschikbaarheid controlerenKYC vereist2% kosten
Huidige impliciete kans
Ja
Ja 0%
Marktkwaliteit

24 / 100

Lage kwaliteit
24u volume

€ 0

Liquiditeit

€ 0

Lage liquiditeit
Bied / Laat

54.0% / 62.0%

Spread

14.8%

Brede spread
Marktdata

Bijgewerkt 11 minuten geleden

17 jun 26, 21:001 jan 27, 4:59

Trends

Uitkomst24uKans
Ja
Ja
0%
Nee
Nee
100%

Gekozen uitkomst

Yes0%

Regels

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.

Gerelateerde Markten

Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

€ 367,9
2026: 33%Manifold MarketsMANIFOLD MARKETS
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

€ 38,3K
Ja: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

€ 5,9K
Ja: 11%PolymarketPOLYMARKET
Measles cases in U.S. by June 30?

Measles cases in U.S. by June 30?

€ 2,2K
2150: 41%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

€ 1,3K
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

€ 994,7
Ja: 22.2%Manifold MarketsMANIFOLD MARKETS

Actief in deze onderwerpen

BitcoinBTC$64,780.07-1.50%EthereumETH$1,762.10-1.75%SolanaSOL$72.60-1.38%DogecoinDOGE$0.0865-1.04%XRPXRP$1.19-1.99%BNBBNB$603.90-0.25%

Gerelateerd Nieuws

Chinese Man Gets 10+ Years for Stealing 107 BTC Using Memorized KeyBlockchain.NewsPentagon adds Alibaba, Baidu and BYD to China’s military-linked list Crypto NewsNvidia’s CEO declines Senate testimony on China’s AI chip businessCrypto NewsChina warns developers over overseas AI relay servicesCrypto NewsChina court treats Bitcoin as property in 107 BTC theft caseCrypto NewsChinese court treats Bitcoin as property in 107 BTC memory theft caseCointelegraph

Regels

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.